J Bone Jt Infect 2018; 3(4):182-186. doi:10.7150/jbji.27718

Short Research Communication

Prolonged Cefoxitin Infusion Using Mobile Elastomeric Infusors In Outpatients With Bone And Joint Infection

Zoé Cavalli1,2, Agathe Becker2,3,4, Alexie Bosch2,3,4, Anne Conrad2,3,4, Claire Triffault-Filit2,3,4, Florent Valour2,3,4,5, Frederic Laurent2,4,5,6, Sabine Cohen7, Christian Chidiac2,3,4, Tristan Ferry2,3,4,5✉

1. Service de Maladies Infectieuses, Hôpital de Mercy, Centre Hospitalier Régional Metz-Thionville, France
2. Université Claude Bernard Lyon 1, Lyon, France
3. Service de Maladies Infectieuses, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, France
4. Centre Interrégional de Référence des Infections Ostéo-articulaires complexes (CRIOAc Lyon), Hospices Civils de Lyon, France
5. Centre International de Recherche en Infectiologie, CIRI, Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL1, Lyon, France
6. Laboratoire de Bactériologie, Institut des Agents Infectieux, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, France
7. Laboratoire de Biochimie, Unité de pharmacologie et toxicologie, Hospices Civils de Lyon, France

Abstract

We reviewed all outpatients with bone and joint infection treated with cefoxitin in continuous intravenous infusion using mobile elastomeric infusors in our regional reference center between 2014 and 2017. The stability of cefoxitin provides an interesting and well-tolerated alternative for continuous infusion in outpatients with polymicrobial bone and joint infection.

Keywords: cefoxitin, infusor, bone, joint

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Cavalli Z, Becker A, Bosch A, Conrad A, Triffault-Filit C, Valour F, Laurent F, Cohen S, Chidiac C, Ferry T. Prolonged Cefoxitin Infusion Using Mobile Elastomeric Infusors In Outpatients With Bone And Joint Infection. J Bone Jt Infect 2018; 3(4):182-186. doi:10.7150/jbji.27718. Available from http://www.jbji.net/v03p0182.htm